Christopher Patusky Sells 1,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $578.88, for a total transaction of $578,880.00. Following the transaction, the director directly owned 1,490 shares of the company’s stock, valued at $862,531.20. The trade was a 40.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Up 1.4%

UTHR opened at $588.38 on Friday. The firm has a 50 day moving average price of $526.73 and a 200-day moving average price of $489.98. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The stock has a market capitalization of $25.79 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same period in the previous year, the company earned $6.19 earnings per share. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. TD Cowen boosted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Ten equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $601.50.

Institutional Trading of United Therapeutics

Large investors have recently added to or reduced their stakes in the business. AE Wealth Management LLC boosted its position in shares of United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC boosted its position in shares of United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc bought a new position in shares of United Therapeutics in the third quarter worth approximately $444,000. Simplify Asset Management Inc. bought a new position in shares of United Therapeutics in the third quarter worth approximately $8,351,000. Finally, Osaic Holdings Inc. boosted its position in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after purchasing an additional 33,662 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Unusual bullish options flow — Traders bought 15,930 UTHR call options on Friday (about a 665% jump versus average call volume), indicating speculative or hedged bullish positioning that can amplify near-term upside or volatility.
• Positive Sentiment: Analyst target increases and constructive coverage — Multiple firms have raised price targets recently (examples cited include Morgan Stanley, Oppenheimer, BofA and RBC) and the consensus remains a “Moderate Buy” with an average target near $601.50, supporting positive investor sentiment. Analyst Coverage & MarketBeat Summary
• Neutral Sentiment: Small CEO sale disclosed — CEO Martine Rothblatt sold 75 shares (March 13) for roughly $40k; the size is immaterial to overall ownership and is unlikely on its own to drive stock direction. InsiderTrades Alert
• Neutral Sentiment: Institutional/hedge fund activity — Several funds adjusted positions (some added, some trimmed); UTHR remains heavily institutionally owned (~94%), which tends to moderate retail-driven swings. MarketBeat: Insider & Institutional Activity
• Negative Sentiment: Material insider selling by CEO — Martine Rothblatt sold 9,500 shares on April 15 (~$5.5M at ~$580.36), a significant reduction in her reported holding per filings; large insider sales can be perceived negatively by investors. SEC Filing: CEO Sale
• Negative Sentiment: Large EVP sale — EVP Paul A. Mahon sold 8,300 shares on April 16 for roughly $4.79M, a meaningful insider disposition that may pressure sentiment if more insider sales follow. SEC Filing: EVP Sale

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.